Cullinan Therapeutics, Inc. (CGEM)

Over the past six months, Cullinan Therapeutics' stock has seen a significant increase, gaining 91.2% over the past 12 months and 40.6% year-to-date as of early May 2026. The FDA accepted the NDA for Zipalertinib on April 28, 2026, making Cullinan eligible for up to $130 million in U.S. regulatory milestones and a 50/50 profit share in the U.S. Cullinan Therapeutics provided corporate updates and reported its Fourth Quarter and Full Year 2025 financial results on March 10, 2026, and First Quarter 2026 financial results on May 7, 2026. The company has participated in several investor conferences. Insider selling activity has been reported. Analyst ratings have been largely positive, with a consensus of "Moderate Buy" and an average price target of $30.00.

As a clinical-stage biopharmaceutical company, Cullinan Therapeutics, Inc. does not have commercialized products or services that would typically exhibit traditional demand seasonality. The "demand" for its "products" is currently driven by the progress of its clinical trials and regulatory milestones, which are not inherently seasonal.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and cancer, operating within the Healthcare sector, specifically in Biotechnology and Drug Discovery. The company focuses on identifying key disease drivers or harnessing the immune system to eliminate diseased cells, leveraging its expertise in T cell engagers. Its major product candidates include CLN-978, Velinotamig, CLN-049, and Zipalertinib (CLN-081/TAS6417).

Cullinan Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, primarily developing therapies for autoimmune diseases and cancer in the United States. Velinotamig has a Phase 1 study initiated in China through a licensing agreement with Chongqing Genrix Biopharmaceutical Co., Ltd.

Cullinan Therapeutics maintains a strong brand reputation, particularly within the investment community, and is viewed as a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Analyst sentiment is overwhelmingly positive, with a consensus rating of "Moderate Buy". The FDA's acceptance of the NDA for Zipalertinib further enhances its reputation and validates its development strategy.

Cullinan Therapeutics, Inc. has significant institutional ownership, with 162 institutional owners holding a total of 62,645,482 shares as of May 2026. The largest individual shareholder is Ansbert Gadicke, who owns 16.16 million shares, representing 26.70% of the company. Other individual insiders also hold a notable percentage of the stock, with insiders collectively owning 7.16% of the stock.